Andere Sprachen Immunotech Biopharm Ltd

Aktien

A2P7YM

KYG4721A1004

6978

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:22 10.05.2024			% 5 Tage	% 1. Jan.
3,39 ^HKD	+3,67 %		-0,29 %	-32,20 %

29.03.	Immunotech Biopharm verbucht 2023 einen Verlust von fast 335 Millionen Yuan	MT
28.03.	Immunotech Biopharm Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023	29.03.
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Immunotech Biopharm Obtains Clinical Trial Nod in China for Leukemia Drug	19.02.
Immunotech Biopharm Receives an Approval of the Investigational New Drug Application for Phase I Clinical Trial from the Centre for Drug Evaluation of the National Medical Products Administration for the aT19 Injection	19.02.
Immunotech Biopharm Ltd Announces First Patient Enrolled in the Phase II Clinical Trialfor Car-T-19 Injection	03.01.
Chinese Drug Regulator Accepts Immunotech Biopharm's Application for AT19 Injection	27.11.
Immunotech Biopharm Enrolls First Patient in Clinical Trial of Lymphoma Drug	07.11.
Immunotech Biopharm Ltd Completes the First Patient Enrolment for its Phase I Clinical Trial for the Denocabtagene Ciloleucel Injection	07.11.
China Grants Breakthrough Therapy Designation to Immunotech's Liver Cancer Medication; Shares Fall 5%	06.09.23
Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	27.08.23
Immunotech Biopharm Ltd Announces Board Changes	27.08.23
Immunotech Biopharm Ltd Announces Director Changes	26.03.23
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	24.03.23
Immunotech Biopharm Obtains China Clinical Trial Approval for Lymphoma Treatment	22.03.23
Immunotech Biopharm Ltd Obtains the Clinical Approval for the Denocabtagene Ciloleucel Injection from the National Medical Products Administration	21.03.23
Immunotech Biopharm Extends Completion Date of Convertible Bond Sale	26.01.23
Immunotech Biopharm’s New Drug Application for Lymphoma Injection Accepted by Chinese Regulator	29.12.22
Immunotech Biopharm Ltd. Receives Acceptance Notice for the Investigational New Drug Application for the Denocabtagene Ciloleucel Injection	28.12.22
Immunotech Biopharm Shareholders to Meet on Convertible Bond Issuance	16.12.22
Immunotech Biopharm Ltd announced that it expects to receive CNY 300 million in funding from Tianjin Tasly Pharmaceutical Co., Ltd., Investment Arm	28.10.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Immunotech Biopharm Ltd

Aktien

A2P7YM

KYG4721A1004

6978

Andere Sprachen

Filter